entertainment -WSS

entertainment

author：focus 2025-09-27 19:28:59 - browse：6

Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the industry says will warp how cancer drugs are developed. On Wednesday, AstraZeneca CEO Pascal Soriot proposed a new solution.

“What we were asking — and are asking now — is a very simple fix,” said Soriot at the STAT Future Summit, saying that “the impact on health care costs would be very marginal.”

The problem, executives say, is that companies developing cancer drugs today generally start small and then go big. They seek approval first in a small setting, such as patients who have exhausted all other therapies, where it’s easiest in terms of trial size and length to show a benefit. Then they go into larger settings, such as newly diagnosed patients, where studies take longer but the revenue potential is much higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Type 2 diabetes prevention programs work at large scale: study

WSS

Healthy food access boosts outcomes in two studies

'Null' research findings aren't empty of meaning. Let's publish them

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

How to ethically and practically extend health care to all

Pharma showers House GOP doctor with campaign cash

Group behind ProMed defends move to subscription

knowledge

entertainment

focus

Supreme Court strikes down use of affirmative action

Physicians aren't 'burning out.' They're suffering from moral injury

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Group behind ProMed defends move to subscription

Medicare proposal to cover medical devices draws a mixed reaction

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Malaria cases in Florida and Texas: Here’s what you need to know

The cancer stories no one wants to hear

DIEP, the 'gold standard' of breast reconstruction, is under threat

Alnylam reports growth in sales of rare disease treatments

leisure time

Alnylam reports growth in sales of rare disease treatments

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Type 2 diabetes prevention programs work at large scale: study

FDA approves Sage Therapeutics’ rapid

The a glaring gap in research on serious mental illness and primary care

CDC recommends RSV monoclonal antibody for infants

focus

entertainment

focus

focus